Cleveland Clinic Taussig Cancer Institute

Taussig Cancer Institute is the hub for Cleveland Clinic Cancer Center.

 

Breast Cancer Update: Review of Breast Cancer Symposia
13:53

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Cleveland Clinic Expert BC Discussion: Commercial CTC Assays, ILD, Role of Lapatinib and Margetuximab, RT After Neoadjuvant ET for DCIS, Survival With Mastectomy vs. Conventional Surgery

FEATURING Megan Miller, Erin Roesch, Jame Abraham
  • 115 views
  • March 8, 2021
12:48

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Prognostic Models & Biomarker Evaluation in mBC: Does Sacituzumab Govitecan Improve PFS in mTNBC? Can CTC Assessments Predict Early Treatment Response? Do CTC Responders Have Improved OS?

FEATURING Erin Roesch
  • 98 views
  • March 8, 2021
  • 1
15:48

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

FEATURING Erin Roesch
  • 200 views
  • March 8, 2021
28:52

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Cleveland Clinic Updates on BC Surgery: How to Refine Axilla Management? Can We Safely Omit Breast Surgery for DCIS? How to Improve QoL?

FEATURING Megan Miller
  • 20 views
  • March 8, 2021
09:00

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Overview of Available Treatment Options in HER2+ MBC: Tucatinib Combo, P+T+D, 2L T-DM1

FEATURING Jame Abraham
  • 235 views
  • March 5, 2021
  • 1
14:19

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

2021 Update on HER2+ MBC: Neratinib/Cape vs. Lapatinib/Cape in MBC, New Oral Pan-HER TKIs, T-DXd, Trastuzumab Duocarmazine, Patritumab Deruxtecan, Margetuximab

FEATURING Jame Abraham
  • 201 views
  • March 5, 2021
  • 1
17:28

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Cleveland Clinic Expert Discussion on BC: Chemo Benefit With Ovarian Suppression in Adjuvant Therapy, Adjuvant Abemaciclib, Neoadjuvant & Hypofractionated RT, Neoadjuvant Carboplatin

FEATURING James Martin, Halle Moore, Eleanor Harris, Megan Kruse
  • 24 views
  • March 5, 2021
24:29

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Cleveland Clinic Updates on IO in mTNBC: Should We Use Atezo With Paclitaxel? Is 1L Pembro+Chemo Effective? Does Paclitaxel/Ipat Provide PFS Benefit vs. Paclitaxel Alone?

FEATURING Megan Kruse
  • 172 views
  • March 5, 2021
08:07

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Cleveland Clinic Updates on IO in Early Stage TNBC: Will pCR Increase With Addition of Atezo in PD-L1+/- Disease? Is There a Decrease in QoL?

FEATURING Megan Kruse
  • 88 views
  • March 5, 2021
21:39

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Cleveland Clinic 2021 BC RT Updates: WBRT vs. APBI, 1-Week vs. 3-Week WBRT, PMRT, Reconstruction

FEATURING Eleanor Harris
  • 26 views
  • March 5, 2021
12:24

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

Breast Cancer Screening and Prevention: Anastrozole vs. Tamoxifen for Postmenopausal Women, Low vs. High Glycemic Index/Load & BC Risk

FEATURING Halle Moore
  • 454 views
  • March 5, 2021
  • 1
10:34

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

BC Survivorship Updates: Diabetes Risk Reduction Diet & Survival, Impact of Sleep on Weight Loss, Targeting Depressive Symptoms in Younger Survivors, Fertility Preservation in Young Patients

FEATURING Halle Moore
  • 17 views
  • March 5, 2021
08:36

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

2021 RxPONDER Study Update on Early HR+/N+ BC: How Does Chemo Affect IDFS for Intermediate-Risk RS Post/Pre-Menopausal Patients?

FEATURING James Martin
  • 212 views
  • March 5, 2021
06:12

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

8-Year Follow-Up on MINDACT Trial for Adjuvant Chemo in HR+/HER2- BC: Do Genomically Low-Risk Tumors Benefit From Chemo? Is DMFS Improved?

FEATURING James Martin
  • 115 views
  • March 5, 2021
09:22

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

2021 Update on ET in BC: Palbociclib+ET in HR+/HER2- Normal Disease After Neoadjuvant Chemo & Surgery, Abemaciclib in High-Risk Early Stage HR+/HER2- Disease - Are There IDFS Benefits?

FEATURING James Martin
  • 132 views
  • March 5, 2021
  • 1